Sequana Medical NV
F:2SE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sequana Medical NV
F:2SE
|
BE |
|
P
|
PTC Inc
F:PMTA
|
US |
|
JCDecaux SE
F:DCS0
|
FR |
|
C
|
Crown Holdings Inc
F:CWN
|
US |
|
H
|
Huaneng Power International Inc
F:HUP1
|
CN |
|
D
|
Deutsche Telekom AG
DUS:DTE
|
DE |
|
B
|
Bank Handlowy w Warszawie SA
XMUN:6HW
|
PL |
|
L
|
Lumentum Holdings Inc
DUS:LU2
|
US |
|
Biprogy Inc
OTC:NTULF
|
JP |
|
Constellation Software Inc
TSX:CSU
|
CA |
|
Equinor ASA
F:DNQ
|
NO |
|
E
|
Eltel AB
F:E5E
|
SE |
|
Macerich Co
NYSE:MAC
|
US |
Wall St Price Targets
2SE Price Targets Summary
Sequana Medical NV
According to Wall Street analysts, the average 1-year price target for
2SE is 1.795 EUR with a low forecast of 1.27 EUR and a high forecast of 2.376 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 2SE's stock price target?
Price Target
1.795
EUR
According to Wall Street analysts, the average 1-year price target for
2SE is 1.795 EUR with a low forecast of 1.27 EUR and a high forecast of 2.376 EUR.
What is the Revenue forecast for Sequana Medical NV?
Projected CAGR
462%
Over the last 8 years, the compound annual growth rate for Revenue has been -28%. The projected CAGR for the next 3 years is 462%.